Evidence map›Paper›PMID 42443912›Full record

ArticleMalaria journal2026

A multi-country non-inferiority experimental hut evaluation of DuraNet

Abel Agbevo, Judicael Nounagnon, Benjamin Menze, Ludovic P Ahoua Alou, Achille Binyang, Boris N'dombidje, Charles Wondji, Raphael N'Guessan, Corine Ngufor

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Abel AgbevoAfrican Institute for Research in Infectious Diseases (AIRID), Cotonou, Benin.
Judicael NounagnonAfrican Institute for Research in Infectious Diseases (AIRID), Cotonou, Benin.
Benjamin MenzeCentre for Research in Infectious Diseases (CRID), Yaoundé, Cameroon.
Ludovic P Ahoua AlouInstitute Pierre Richet, Bouaké, Cameroon.
Achille BinyangCentre for Research in Infectious Diseases (CRID), Yaoundé, Cameroon.
Boris N'dombidjeAfrican Institute for Research in Infectious Diseases (AIRID), Cotonou, Benin.
Charles WondjiCentre for Research in Infectious Diseases (CRID), Yaoundé, Cameroon.
Raphael N'GuessanLondon School of Hygiene and Tropical Medicine (LSHTM), London, WC1E 7HT, UK.
Corine NguforAfrican Institute for Research in Infectious Diseases (AIRID), Cotonou, Benin. corine.ngufor@lstmed.ac.uk.ORCID https://orcid.org/0000-0002-7755-9609

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPyrethroid-piperonyl butoxide (PBO) nets enhance malaria vector control by counteracting metabolic resistance mechanisms in malaria vectors through the synergistic action of PBO. DuraNet

methodsExperimental hut trials were conducted at three ecologically and entomologically distinct sites with pyrethroid-resistant vector populations: Covè, Benin (Anopheles gambiae s.l.), Mibellon, Cameroon (An. funestus), and M'bé, Côte d'Ivoire (An. gambiae s.l.). Each net type was tested unwashed and after 20 standardized washes. Primary outcomes included 24-h mosquito mortality and blood-feeding inhibition. DuraNet

resultsDuraNet

conclusionDuraNet

Indexed as

AnophelesInsecticide ResistanceInsecticidesInsecticide-Treated BednetsMalariaMosquito ControlMosquito VectorsPiperonyl ButoxidePyrethrinsAfrica, CentralAfrica, WesternAnimalsBeninCameroonFemalecypermethrinInsecticidesPiperonyl ButoxidePyrethrinsAnopheles funestusAnopheles gambiae s.l.BeninCameroonCôte d’IvoireCovèDuraNet plusExperimental hutsInsecticide treated netsM’béMibellonNoninferiorityPiperonyl butoxidePyrethroid-PBO nets

Identifiers

PMID42443912
PMCPMC13647675

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.